Paxlovid

• COVID-19 treatment in high-risk adults
• Prevention of COVID-19 hospitalization
• Prevention of COVID-19 death
• Treatment of mild-to-moderate COVID-19 in eligible patients

Paxlovid is a fixed-combination oral antiviral consisting of nirmatrelvir (a SARS-CoV-2 main protease inhibitor) and ritonavir (a CYP3A4 inhibitor that boosts nirmatrelvir levels). It is indicated for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years and older weighing at least 40 kg who are at high risk for progression to severe disease. When started within 5 days of symptom onset, Paxlovid substantially reduces hospitalization and death in unvaccinated high-risk patients and provides additional benefit even on top of vaccination in older adults and the immunocompromised. Its main practical challenge is the long list of drug interactions caused by ritonavir, which means a careful medication review is the most important step before prescribing. Originally authorized under emergency use in late 2021, Paxlovid received full FDA approval for adults in May 2023 and remains under EUA for eligible pediatric patients.

Mechanism of Action

Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 3C-like protease (3CLpro, also called Mpro), a viral enzyme essential for processing the polyproteins that the virus uses to assemble new viral particles. By covalently binding the active-site cysteine of 3CLpro, nirmatrelvir halts viral replication at the polyprotein-cleavage step. Without ritonavir, nirmatrelvir is rapidly metabolized by the liver enzyme CYP3A4, leading to subtherapeutic blood levels. Ritonavir is included not for its antiviral activity but as a pharmacokinetic booster — a potent CYP3A4 inhibitor that slows nirmatrelvir clearance and keeps levels in the antiviral range across the 12-hour dosing interval. The price of this boost is dramatic CYP3A4 inhibition that affects countless co-prescribed medications. The 3CLpro target is highly conserved across SARS-CoV-2 variants, which is why Paxlovid has retained activity through successive Omicron sublineages while monoclonal antibody therapies have lost effectiveness. Resistance mutations have been documented in vitro and rarely in vivo, but clinically meaningful resistance has not yet emerged at scale.

Clinical Use

The CDC and NIH COVID-19 treatment guidelines recommend Paxlovid as the preferred outpatient antiviral for non-hospitalized patients at high risk for progression to severe COVID-19. High-risk groups include adults age 65 and older (with risk increasing sharply above age 75), those with chronic kidney disease, diabetes mellitus, coronary artery disease, heart failure, COPD, moderate to severe asthma, obesity (BMI 30 or greater), pregnancy, immunocompromise from medications or disease, current or former smoking, sickle cell disease, mental health conditions including depression, and several other conditions on the CDC list. The alternative oral antiviral molnupiravir is less effective and reserved for patients who cannot take Paxlovid because of interactions or renal contraindications. Intravenous remdesivir for 3 days is an option in select circumstances and may be preferred when oral intake is unreliable or interactions are unmanageable. Knowing how to distinguish COVID-19 from influenza, RSV, and the common cold helps patients seek testing and treatment within the critical 5-day window. Annual COVID-19, influenza, and updated pneumococcal vaccines remain the highest-value preventive interventions and are reviewed at every visit for high-risk patients.

How to Take It

Paxlovid is dispensed in a daily blister pack containing two 150 mg nirmatrelvir tablets (pink) and one 100 mg ritonavir tablet (white) per dose, taken together by mouth twice daily for 5 days. Swallow the tablets whole; do not crush, chew, or split. They can be taken with or without food. Start treatment as soon as possible after a positive test and within 5 days of symptom onset — earlier is better, and starting at day 4 or 5 still provides benefit. Complete the full 5-day course even if you feel better quickly; stopping early may contribute to viral rebound and theoretical resistance pressure. If a dose is missed by less than 8 hours, take it as soon as you remember; if more than 8 hours have passed, skip the missed dose and resume your regular schedule — do not double up. The most distinctive side effect is dysgeusia, a metallic, bitter, or unusual taste, which begins on day 1 and resolves within a few days of completing the course; sucking on hard candy, drinking flavored water, and brushing teeth more frequently can help. Mild diarrhea, nausea, abdominal discomfort, and a small bump in blood pressure are also common but typically self-limited. Hold or substitute interacting medications under your prescriber's guidance for the 5-day course plus 2-3 days afterward.

Monitoring and Follow-Up

Before prescribing, your clinician will perform a comprehensive medication reconciliation — including over-the-counter products, supplements, and herbals — to identify and manage interactions. Common adjustments include temporarily holding statins like simvastatin and atorvastatin (use pravastatin or rosuvastatin at reduced dose instead), reducing or holding certain immunosuppressants like tacrolimus, avoiding combination with certain antiarrhythmics, sedatives like [midazolam] or [triazolam], ergot derivatives, and several anti-seizure medications. An eGFR within 3-6 months guides dosing — moderate renal impairment (eGFR 30-59 mL/min) requires a reduced dose (one 150 mg nirmatrelvir tablet plus 100 mg ritonavir twice daily), and severe renal impairment (eGFR less than 30) is a contraindication for the standard regimen. After completing therapy, monitor for symptom resolution. COVID-19 rebound (recurrence of symptoms and a positive test) occurs in roughly 5-10% of patients 2-8 days after finishing Paxlovid; rebound is generally mild and self-limited and does not require retreatment per current guidance, although patients with rebound should re-isolate. Liver enzymes can be checked in patients with baseline hepatic disease, and blood pressure can be monitored at home if hypertension is a known issue.

Special Populations

Paxlovid is not recommended in severe renal impairment (eGFR less than 30 mL/min) or severe hepatic impairment (Child-Pugh C). Pregnancy data are limited but generally reassuring, and pregnant patients are themselves a high-risk group who may benefit from treatment — risks and benefits should be discussed individually. Lactation: short pauses in breastfeeding are not generally recommended; the small amounts of drug in breast milk are unlikely to harm the infant. Older adults frequently have polypharmacy — interaction screening is critical, and arrangements for monitoring should be in place. Pediatric use is limited to those 12 and older meeting the weight criterion. Solid-organ transplant recipients require coordination with their transplant team because of complex immunosuppressant interactions. Patients with HIV on ritonavir-containing regimens already need careful interaction review. Patients living alone should have a contact person for symptom check-ins during the 5-day course.

When to Contact Your Doctor

Seek emergency care for difficulty breathing, persistent chest pain, confusion, bluish lips or face, or inability to stay awake — these are warning signs of severe COVID-19 regardless of whether you are on Paxlovid. Call the office for a rash that is spreading, swelling of the face or throat, persistent vomiting that prevents you from completing the course, severe abdominal pain, dark urine or jaundice suggesting liver injury, or symptoms that worsen on or after Paxlovid. Pulse oximetry at home is helpful for high-risk patients; sustained readings below 94% (or below 92% in patients with chronic lung disease at baseline) warrant prompt re-evaluation.

A few practical points often come up. Home antigen tests are convenient but less sensitive than PCR; a negative antigen test in a symptomatic high-risk person within the first day or two of symptoms should generally be repeated 24-48 hours later or confirmed with PCR. Telehealth visits are well-suited to Paxlovid evaluation because the encounter is largely about reviewing medications, risk factors, and renal function. A pharmacist test-and-treat program is now available in many locations as well, although patients with complex medication regimens benefit from physician oversight to ensure interaction screening is thorough. After Paxlovid, isolation guidance generally follows CDC recommendations: stay home until fever-free for 24 hours without antipyretics and symptoms are improving, then mask in indoor public settings for additional days. If rebound occurs, re-isolation is reasonable for that period. Long COVID risk appears reduced by early antiviral treatment in observational studies, although randomized data are still maturing — yet another reason to seek treatment promptly when eligible.

If you have tested positive for COVID-19 or believe you are at higher risk and want to confirm your treatment plan, contact us or schedule a visit at Zimmer Medical Group — early evaluation matters because the 5-day treatment window is short and the benefit of antivirals is greatest when started in the first 48 hours.